Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


New Products In Brief

This article was originally published in The Gray Sheet

Executive Summary

Debuts include St. Jude’s Assura ICDs in Europe and Edwards’ Perimount mitral heart valve in China.

You may also be interested in...

Edwards’ Pursuit Of Transcatheter Mitral Valve Repair Options Continues, CEO Says

During the recent Wilson Sonsini Goodrich & Rosati Medical Device Conference in San Francisco, Edwards Lifesciences CEO Michael Mussallem offered candid remarks on his firm’s continued interest in developing a minimally invasive mitral valve repair product.

New Products In Brief

HeartWare ventricular assist device gains expanded labeling in Europe. Medigus gets 510(k) clearance for endoscopic GERD treatment. More new products.

New Products In Brief

Recent product approvals and launches include St. Jude’s Assura and Ellipse ICDs, Boston Scientific’s Ingenio pacemakers and Medtronic’s Valiant Captivia thoracic stent graft system.


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts